Clinical Trial Update: Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating panitumumab in combination with irinotecan as second-line therapy for metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Vectibix (panitumumab)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED